Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...
Jefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...
Madrigal Pharmaceuticals stock jumps on MASH drug hopes
Madrigal Pharmaceuticals (MDGL) shares jumped after Novo Nordisk (NVO) announced that a trial showed its weight-loss drug ...
Montgomery County firm's shares soar on huge sales increase of flagship drug
Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
FiercePharma6d
It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash
In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...
BioPharma Dive5d
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...
ETF Daily News3d
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Unusually-High Trading Volume Following Strong Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) saw unusually-high trading volume on Friday following a better than expected earnings announcement.Approximately 560,141 shares ...